A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Reference Study ID Number: GO42784 https://forpatients.roche.com/
Szpital Morski Im. Pck; Oncology & Radiotherapy Dept(2.2 mi away)Contact
+662 other location
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the
efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's
choice in participants with medium- and high-risk Stage I-III histologically confirmed
estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative
early breast cancer.
Early Breast Cancer
Endocrine Therapy of Physician's Choice
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.